Murrough discusses ADAA 2026 findings evaluating azetukalner in MDD with anhedonia; exploratory outcomes suggest potential benefit despite nonsignificant primary endpoints.
James Murrough, MD, PhD
Advertisement
James Murrough, MD, PhD, from the Icahn School of Medicine at Mount Sinai.
Articles by James Murrough, MD, PhD
Phase 2 data presented at ADAA 2026 suggest azetukalner may improve anhedonia in MDD, even though the trial did not meet its primary neuroimaging endpoint.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
2
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
3
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
4
What Are the Side Effects of Hair and Skin Supplements in Dermatology? With Rajani Katta, MD
5